As usual - I think that the ridicule is being sourced by the same nagging and lingering concerns.
1) The IND and beginning of testing of the Shingles-treatment has been 'promised' for years now and still isn't underway. This makes it easy for the typical detractor sources to generate ridicule.
2) The 'shift' (at least perceived as a shift) to the flavor of the month (in this case coronavirus treatments) fits the old pattern from the last decade for NNVC - which makes ridicule easy to do.
3) NNVC (to our knowledge) hasn't even begun negotiating with Diwan's private companies for a license for a coronavirus drug application - which again - makes ridiculing the company an easy task.
And in the meantime the company continues to appear to spin it's wheels and slowly drain out money.
Market Data 
Markets 
AI
